Common Stock, par value $0.0001 per share
- Symbol
- VANI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Vivani Medical, Inc.
VANINASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 . Regulation FD Disclosure. Vivani Medical, Inc. (the “Company” or “Vivani”) made a presentation at the Emerging Growth Conference in New York on Wednesday, July 15, 2026 at 4:10 p.m. Eastern Time. A copy of a slide presentation that Dr.…
Company context
Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.
Current securities
Historical securities (6)
EYESNASDAQ · EQUITY · Historical · closed Aug 30, 2022EYESNASDAQ · EQUITY · Historical · closed Aug 30, 2022EYESNASDAQ · ETF · Historical · closed Oct 22, 2026EYESWNASDAQ · WARRANT · Historical · closed Aug 30, 2022VANIWOTC · WARRANT · Historical · closed Mar 13, 2024VANIWOTC · WARRANT · Historical · closed Mar 13, 2024
Registered securities in this filing
Vivani Medical, Inc. · 8-K · Filed 2026-07-16
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01
.
Regulation FD Disclosure.
Vivani Medical, Inc. (the “Company” or “Vivani”) made a presentation at the Emerging Growth Conference in New York on Wednesday, July 15, 2026 at 4:10 p.m. Eastern Time. A copy of a slide presentation that Dr. Adam Mendelsohn, Vivani’s Chief Executive Officer, used during the conference, which includes an update that the expected date for the Company’s first dosing of SLIM-1 is expected to take place in August 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The slide presentation speaks only as of the date of this Current Report on Form 8-K. While Vivani may elect to update the slide presentation in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Vivani specifically disclaims any obligation to do so.
The information contained in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information contained in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.
Filed exhibits (1)
EX-99.1
Open exhibit ↗